Genomma Lab Internacional SAB de CV (MEX:LABB, Financial) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus estimate for Q3 2024 revenue is $4,604.32 million, and the earnings are expected to come in at $0.52 per share. The full year 2024's revenue is expected to be $17.73 billion and the earnings are expected to be $1.84 per share. More detailed estimate data can be found on the Forecast page.
Genomma Lab Internacional SAB de CV (MEX:LABB, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Genomma Lab Internacional SAB de CV (MEX:LABB) for the full year 2024 have increased from $17.32 billion to $17.73 billion, and for 2025 from $18.84 billion to $19.07 billion. Earnings estimates have also risen, from $1.68 per share to $1.84 per share for 2024, and from $1.93 per share to $2.09 per share for 2025.
Genomma Lab Internacional SAB de CV (MEX:LABB, Financial) Reported History
In the previous quarter of June 30, 2024, Genomma Lab Internacional SAB de CV's (MEX:LABB) actual revenue was $4,651.50 million, which beat analysts' revenue expectations of $4,520.25 million by 2.9%. Genomma Lab Internacional SAB de CV's (MEX:LABB) actual earnings were $0.67 per share, which beat analysts' earnings expectations of $0.447 per share by 49.89%. After releasing the results, Genomma Lab Internacional SAB de CV (MEX:LABB) was down by -1.36% in one day.
Genomma Lab Internacional SAB de CV (MEX:LABB, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 9 analysts, the average target price for Genomma Lab Internacional SAB de CV (MEX:LABB) is $22.40 with a high estimate of $28 and a low estimate of $15. The average target implies a downside of -8.27% from the current price of $24.42.
Based on GuruFocus estimates, the estimated GF Value for Genomma Lab Internacional SAB de CV (MEX:LABB, Financial) in one year is $19.55, suggesting a downside of -19.94% from the current price of $24.42.
Based on the consensus recommendation from 9 brokerage firms, Genomma Lab Internacional SAB de CV's (MEX:LABB, Financial) average brokerage recommendation is currently 2.4, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
